Teleflex Incorporated Stock News

Teleflex Incorporated (NYSE:TFX ) Q2 2025 Earnings Call July 31, 2025 8:00 AM ET Company Participants John R. Deren - Executive VP & CFO Lawrence Soren Keusch - Vice President of Investor Relations & Strategy Development Liam J.

WAYNE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable September 15, 2025, to shareholders of record at the close of business on August 15, 2025.

WAYNE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the second quarter ended June 29, 2025.

The global Chest Drainage Catheters Market, covering product types like thoracic and pleural drainage catheters and applications in cardiothoracic surgery and pneumothorax, is forecast to grow with a CAGR of 4.78% from 2025 to 2032. This expansion is driven by the increasing prevalence of chronic diseases and advances in minimally invasive procedures. North America is set to dominate the market...

WAYNE, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, July 31, 2025.

WAYNE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that it has completed the previously announced acquisition of substantially all of the Vascular Intervention business of BIOTRONIK SE & Co. KG. The acquisition adds a broad portfolio of therapeutic products to Teleflex's portfolio of interventional a...

WAYNE, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced findings from a new multinational study reporting efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters (CVCs). This prospective cohort study included more than 6,670 patients from 12 Intensive care units in eight hospitals across In...

Timed with National Men's Health Month, the Prostate Monster ad campaign shines a light on quality-of-life issues associated with benign prostatic hyperplasia or BPH—a condition affecting millions of men 1 —and encourages them to take control of their health.